EP1077704A4 - Kombinationstherapie zur behandlung der depression - Google Patents

Kombinationstherapie zur behandlung der depression

Info

Publication number
EP1077704A4
EP1077704A4 EP99921795A EP99921795A EP1077704A4 EP 1077704 A4 EP1077704 A4 EP 1077704A4 EP 99921795 A EP99921795 A EP 99921795A EP 99921795 A EP99921795 A EP 99921795A EP 1077704 A4 EP1077704 A4 EP 1077704A4
Authority
EP
European Patent Office
Prior art keywords
depression
treatment
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99921795A
Other languages
English (en)
French (fr)
Other versions
EP1077704A1 (de
Inventor
David Michelson
Gary Dennis Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1077704A1 publication Critical patent/EP1077704A1/de
Publication of EP1077704A4 publication Critical patent/EP1077704A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99921795A 1998-05-21 1999-05-10 Kombinationstherapie zur behandlung der depression Withdrawn EP1077704A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8626898P 1998-05-21 1998-05-21
US86268P 1998-05-21
PCT/US1999/010092 WO1999059593A1 (en) 1998-05-21 1999-05-10 Combination therapy for treatment of depression

Publications (2)

Publication Number Publication Date
EP1077704A1 EP1077704A1 (de) 2001-02-28
EP1077704A4 true EP1077704A4 (de) 2002-01-30

Family

ID=22197424

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99921795A Withdrawn EP1077704A4 (de) 1998-05-21 1999-05-10 Kombinationstherapie zur behandlung der depression

Country Status (5)

Country Link
EP (1) EP1077704A4 (de)
JP (1) JP2002515435A (de)
AU (1) AU3891299A (de)
CA (1) CA2332253A1 (de)
WO (1) WO1999059593A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
GB2362826A (en) * 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US20020107244A1 (en) * 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
JPWO2004014429A1 (ja) * 2002-08-09 2005-12-02 三菱ウェルファーマ株式会社 精神疾患発症脆弱性制御剤
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP2006506461A (ja) * 2002-10-25 2006-02-23 コルジウム ファーマシューティカル, インコーポレイテッド ミルナシプランのパルス型放出組成物
PT1575590E (pt) 2002-12-27 2007-12-06 Otsuka Pharma Co Ltd Derivados de carboestirilo e inibidores da reabsorção de serotonina para o tratamento de distúrbios de humor
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
EP1795196A3 (de) * 2003-04-04 2008-02-06 Dynogen Pharmaceuticals, Inc. Verfahren zur Behandlung von Erkrankungen der unteren Harnwege
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
EP1713486A4 (de) 2003-12-02 2009-04-29 Sheldon Leslie James Kombinationstherapie für demenz, depression und apathie
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
EP1094818A1 (de) * 1998-05-19 2001-05-02 Dalhousie University Verwendung tricyclischer antidepressiva zur lokalen analgesie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973594A (en) * 1986-12-17 1990-11-27 Glaxo Group Limited Medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
EP1094818A1 (de) * 1998-05-19 2001-05-02 Dalhousie University Verwendung tricyclischer antidepressiva zur lokalen analgesie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'SOUZA, D.L. ET AL.: "Effect of alosetron on the pharmacokinetics of fluoxetine", J CLIN PHARMACOL, vol. 41, 2001, pages 455 - 458, XP001034110 *
KORIECH, O.M.: "Fluoxetine treatment comprises the antiemetic efficacy of ondasetron in cancer patients", CLINICAL ONCOLOGY, vol. 7, 1995, pages 371 - 372, XP001034101 *
See also references of WO9959593A1 *

Also Published As

Publication number Publication date
EP1077704A1 (de) 2001-02-28
AU3891299A (en) 1999-12-06
WO1999059593A1 (en) 1999-11-25
JP2002515435A (ja) 2002-05-28
CA2332253A1 (en) 1999-11-25

Similar Documents

Publication Publication Date Title
EP1077704A4 (de) Kombinationstherapie zur behandlung der depression
GB9824436D0 (en) Methods of treatment
EP1063990A4 (de) Therapie von estrogenabhängigen erkrankungen
PL344304A1 (en) Combination therapy for treatment of bipolar disorders
PL344331A1 (en) Combination therapy for treatment of refractory depression
IL142588A0 (en) Therapy for improving cognition
HU0002509D0 (en) Combination therapy for treatment of migraine
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
IL135994A0 (en) Combination therapy for the treatment of aids
HU0002508D0 (en) Combination therapy for treatment of migraine
EP0981545A4 (de) Behandlung von osteoporose
IL136025A0 (en) Combination therapy for the treatment of migraine
GB9819999D0 (en) Treatment of cancer
GB0020261D0 (en) Therapeutic treatment
IL136024A0 (en) Combination therapy for the treatment of migraine
GB2343629B (en) Treatment of cellulite
GB9704174D0 (en) Agent for medical treatment
IL120955A0 (en) Treatment of osteoporosis
PL346528A1 (en) Treatment of depression
ZA9810306B (en) Combination therapy for the treatment of aids
GB9721978D0 (en) Treatment of depression
GB9819590D0 (en) Combination therapy for the treatment of aids
GB9807938D0 (en) Combination therapy for the treatment of AIDS
SI1068199T1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001120;LT PAYMENT 20001120;LV PAYMENT 20001120;RO PAYMENT 20001120;SI PAYMENT 20001120

A4 Supplementary search report drawn up and despatched

Effective date: 20011218

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/55 A, 7A 61K 31/44 B, 7A 61K 31/415 B, 7A 61K 31/445 B, 7A 61K 31/34 B, 7A 61K 31/15 B, 7A 61K 31/135 B, 7A 61K 31/38 B, 7A 61K 31/55 J, 7A 61K 31:135 J, 7A 61K 31:38 J, 7A 61K 31:445 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020302

R18D Application deemed to be withdrawn (corrected)

Effective date: 20020301